Taguchi, Akira http://orcid.org/0000-0003-2620-1487
Tanaka, Shiro
Ozaki, Tatsuro
Arai, Koshiro
Mori, Satoshi
Ohta, Hiroaki
Hagino, Hiroshi
Tanaka, Sakae
Shiraki, Masataka
Nakamura, Toshitaka
Soen, Satoshi
,
Funding for this research was provided by:
Japan Society for the Promotion of Science London (21K09885)
Japan Society for the Promotion of Science (22K10208)
Public Health Research Foundation
Japan Agency for Medical Research and Development (19lk0201061t0004)
Article History
Received: 29 May 2023
Accepted: 27 August 2023
First Online: 28 October 2023
Declarations
:
: A. Taguchi has received lecture fees from Asahi Kasei Pharma Corp., Daiichi Sankyo Co. Ltd., Chugai Pharmaceutical Co. Ltd., and Teijin Pharma Ltd. He has received a consultation fee from Media Corp. Ltd. Shiro Tanaka has received lecture fees from Bayer Yakuhin, Amgen Astellas BioPharma K.K., and the Research Institute of Healthcare Data Science. He has received consultation fees and outsourcing fees from Daiichi Sankyo Company, Limited, Boehringer Ingelheim, Satt, and the Public Health Research Foundation. He has received research grants from the Japan Agency for Medical Research and Development, the Japanese Ministry of Health Labor and Welfare, the Japanese Ministry of Education, Science, and Technology, and Novo Nordisk. He engaged in a research project of the Japan Agency for Medical Research and Development. H. Hagino has received lecture fees or grants outside the submitted work from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Mochida Pharma Corp., Taisho Pharmaceutical Co., Ltd., Teijin Pharma Co., Ltd., and UCB Japan. S. Soen has received consulting fees, speaking fees, and/or honoraria from Amgen, Asahi Kasei Pharma, Astellas Pharma, Chugai, Daiichi Sankyo, Eisai, Ono, Teijin Pharma, and UCB Japan. T. Ozaki, K. Arai, S. Mori, H. Ohta, Sakae Tanaka, M. Shiraki, and T. Nakamura have no conflicts of interests.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The protocol of the Japanese Osteoporosis Intervention Trial-05 (JOINT-05) was approved by the certified review board of Toranomon Hospital and the central ethics committee of the Adequate Treatment of Osteoporosis (A-TOP) research group.
: All patients provided written informed consent.
: All patients provided written informed consent.